SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Titan Pharmaceuticals, Inc. (TTNP)

July 30, 2025 10:44 AM EDT | Source: Brodsky & Smith

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - July 30, 2025) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Titan Pharmaceuticals, Inc. ("Titan" or the "Company") (NASDAQ - TTNP) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to KE Sdn. Bhd. ("KE"). Upon completion of the Merger, the existing security holders of KE and Titan expect to own approximately 86.7% and 13.3%, respectively, of the outstanding shares of the combined company.

The investigation concerns whether the Titan Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.

If you own shares of Titan stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, visit https://www.brodskysmith.com/cases/titan-pharmaceuticals-inc-nasdaq-ttnp-2/, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260682

info